anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a virus infection-preventive agent for domestic animals effectively preventing an infection by a herpesvirus of e.g. Aujeszky's disease virus or coronavirus of e.g. swine infectious gastroenteritis virus and apart from any side effects harmfully bio-active by including a tea-derived polyphenol as an active ingredient. SOLUTION: This medicinal agent is obtained by including a tea-derived polyphenol of e.g. an tea extract extracted from tea with water or a hot water, etc., as an active agent. The usage of the agent is pref. e.g. to administer a feedstuff or drink for domestic animals mixed therewith to the animals or to sprinkle a water admixed therewith on the animals, etc., from the above of their corrals, etc., for spreading it on their skins. For example, the blending ratio of the polyphenol is pref. 0.1 to 0.6% based on the animal feedstuff or drink, and 0.01 to 0.6% based on the sprinkling water.
The invention relates to a incense, in particular to a formula and a preparation process of ginseng incense. The formula comprises 20-40 parts of ginseng root, 20-30 parts of agilawood, 30-60 parts of sandalwood, 10-30 parts of agilawood, 5-15 parts of ginseng leaf and 10-40 parts of plant sticky powder. The preparation process comprises the following steps: pulverizing the raw materials into powder, granulating for at least three times, extruding into specified shape in an extruder, naturally air drying for 24 hr to obtain semi-finished product, uniformly spraying gelatinized starch solution on the surface to make the surface adhere to folium Ginseng powder, and storing in cellar for 3 months to obtain Ginseng radix incense. The invention adopts the granulator for granulation after mixing, the spice is fully mixed, and the bonding effect is good. The invention totally adopts a secondary adhesion process of pure natural plant adhesive and gelatinized starch, so that the ginseng is tightly filled, the ginseng powder on the surface is covered, the ginseng fragrance is fully combusted, and the occurrence of fragrance breaking is avoided. The invention is made of pure natural materials, has the pharmacological effects of calming, bacteriostasis, resisting cancer, improving myocardial ischemia and the like, and can greatly improve the immunity of human bodies after being used for a long time.
AIMS: Circular RNAs (circRNAs) are considered important regulators of biological processes, but their impact on atherosclerosis development, a key factor in coronary artery disease (CAD), has not been fully elucidated. We aimed to investigate their potential use in patients with CAD and the pathogenesis of atherosclerosis.
METHODS AND RESULTS: Patients with stable angina (SA) or acute coronary syndrome (ACS) and controls were selected for transcriptomic screening and quantification of circRNAs in blood cells. We stained carotid plaque samples for circRNAs and performed gain- and loss-of-function studies in vitro. Western blots, protein interaction analysis, and molecular approaches were used to perform the mechanistic study. ApoE-/- mouse models were employed in functional studies with adeno-associated virus-mediated genetic intervention. We demonstrated elevated circARCN1 expression in peripheral blood mononuclear cells from patients with SA or ACS, especially in those with ACS. Furthermore, higher circARCN1 levels were associated with a higher risk of developing SA and ACS. We also observed elevated expression of circARCN1 in carotid artery plaques. Further analysis indicated that circARCN1 was mainly expressed in monocytes and macrophages, which was also confirmed in atherosclerotic plaques. Our in vitro studies provided evidence that circARCN1 affected the interaction between HuR and ubiquitin-specific peptidase 31 (USP31) mRNA, resulting in attenuated USP31-mediated NF-κB activation. Interestingly, macrophage accumulation and inflammation in atherosclerotic plaques were markedly decreased when circARCN1 was knocked down with adeno-associated virus in macrophages of ApoE-/- mice, while circARCN1 overexpression in the model exacerbated atherosclerotic lesions.
CONCLUSIONS: Our findings provide solid evidence macrophagic-expressed circARCN1 plays a role in atherosclerosis development by regulating HuR-mediated USP31 mRNA stability and NF-κB activation, suggesting that circARCN1 may serve as a factor for atherosclerotic lesion formation.
The technical problem of the present invention is to provide a novel peptide capable of treating, preventing or improving mood disorders. The present invention provides a peptide having an amino acid sequence of SEQ ID NO. 1 or SEQ ID NO. 2 and having an amino acid length of 3 to 5 inclusive. The peptide may have an amino acid sequence of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, or SEQ ID NO. 4.
Following an overnight fast of at least 10 hours, participants will be administered 100 mg midomafetamine (equivalent to 120 mg midomafetamine HCl) with 240 mL of water. No food should be allowed for at least 4 hours post-dose.
The overall study design is a prospective, single centre, cohort study in patients who have suspected pulmonary Invasive Aspergillosis (IA)/IFD and hence have a diagnostic BAL as part of their clinical care. A total number of 20 children \<18 years of age undergoing a BAL for suspected IA/IFD at St George's Hospital University Hospitals NHS Foundation Trust (United Kingdom) will be enrolled. No changes in the regular diagnostic pathway or treatment will be done for this study.

If patients are scheduled to have a BAL sample and meet the Inclusion/Exclusion criteria the patients will be approached for consent at the same time as consent for the standard of care BAL procedure. With the patients consent the samples will be retrieved from the BAL fluid, both for the standard of care investigations (fungal culture, GM and fungal PCR in BAL fluid) and for the study sample. The minimal study sample required will be 1 ml. The study samples will be tested directly with the LFD for Aspergillus antigen when possible. Haemorrhagic or too viscous samples will need to be previously treated with a buffer (150 ul BAL with 300 ul buffer). Every individual participant patient will be followed up prospectively at two weeks and 3-months post-BAL to collate information.
FIELD: medicine. SUBSTANCE: method involves exposing mammary gland surface to ultraviolet radiation. Then permanent magnetic field is applied to the mammary gland. Segmental massage of the neck and back, reflexogenic massage of feet, ear concha and cosmetic massage of the mammary glands are carried out. Thoracic muscles electrostimulation is performed. Placenta extraction and nicotinic acid ionophoresis are applied to the area of mammary glands. Biologically active points on forearm and chest surface are subjected to heat stimulation. The treatment is finished with local negative decompression of the mammary glands. Relaxation massage, aromatherapy and musical therapy are applied. EFFECT: significant growth and removed asymmetry of mammary glands. 2 cl
Recently, the debate surrounding the use of mesh in urogynecological procedures has intensified, leading to FDA warnings and heightened safety concerns. This clinical opinion emphasizes the vital need to specify mesh types in these procedures, drawing attention to the risk profiles and clinical outcomes associated with various meshes and the procedures that utilize them. A significant issue identified in contemporary literature is the tendency to group diverse mesh types under the same umbrella, disregarding their unique characteristics and applications. We describe the range of mesh types, their application routes, and associated complications, highlighting the risks of this nonspecific approach to patient safety and informed decision making. We critically examine the generalization of mesh terminology in clinical and research dialogues. Concluding with specific recommendations for health care providers and researchers, the paper advocates for a more nuanced understanding and communication in the field, ultimately aiming to improve patient care and safety in urogynecological practice.
In the clinic, physicians are reluctant to use thrombolysis, Defibrase and anticoagulation therapy because of the severity of symptoms, poor prognosis, risk of hemorrhage and high fatality rate that occur with acute massive cerebral infarction. Nimodipine, as a selective Ca2+ antagonist, is highly liposoluble, effectively crosses the blood-brain barrier, selectively acts on intracranial blood vessels, and is an accepted neuroprotective agent that can be applied in the clinic. The aim of the present study is to perform a double-blind, randomized and controlled trial of the clinical efficacy and safety of nimodipine administered as an intravenous drip in the early stages of acute massive cerebral infarction.

Patients will receive nimodipine within 3 days of infarction onset. We will closely monitor the following: (1) Blood pressure and heart rate of the patient before treatment, since nimodipine is contraindicated in patients with hypotension and low heart rate. Where blood pressure is ≥ 100/80 mmHg and heart rate ≥ 60 BPM, nimodipine will be administered. (2) Speed of infusion. This should not be too fast; we suggest 1-2 drops per minute initially, increasing gradually until the drop in systolic pressure exceeds 10 mmHg. The average drip speed should be 6-8 drops/minute, and the fastest drip speed 10 drops/minute. (3) During the infusion, physicians should monitor adverse reactions such as headache, dizziness, flushing or sweating. If any occur, the infusion speed must be reduced. If the patients remain uncomfortable, nimodipine should be withdrawn. (4) Liver and kidney function should be monitored throughout nimodipine administration.

Although nimodipine is relatively safe, there is still a risk of some adverse effects, such as cardiovascular system reactions (blood pressure decreases, bradycardia, angina, and atrioventricular block), headache, dizziness, edema, and liver and kidney dysfunction. It is necessary to determine the optimal therapeutic time window and dose of nimodipine in multi-center, large-scale clinical trials.
Routine hemostasis parameters such as prothrombin time and fibrinogen are frequently abnormal in patients with chronic liver disease and have been demonstrated to be poor predictors for periprocedural bleeding. Alterations in procoagulant and anticoagulant factors in this population result in a state of rebalanced hemostasis, which is not reflected by routine hemostatic measures. Viscoelastic hemostatic assays (VHA) present a point of care measure of global hemostasis with an emerging role in guiding transfusion in the liver transplant setting. The potential role for VHA in guiding periprocedural transfusion is unknown. Here we critically appraise the available limited evidence on the use of VHA to guide prophylactic treatment in patients with cirrhosis undergoing procedures. We assess whether the impact of a VHA-guided approach improves clinical outcomes. Suggested areas for future research with a focus on clinically relevant outcomes, particularly periprocedural bleeding, are highlighted.
Tolvaptan can cause serious and potentially fatal liver injury. In placebo-controlled studies and an open-label extension study of chronically administered tolvaptan in patients with ADPKD, cases of serious liver injury attributed to tolvaptan, generally occurring during the first 18 months of therapy, were observed. In postmarketing experience with tolvaptan in ADPKD, acute injury resulting in liver failure requiring liver transplantation has been reported. Tolvaptan should not be used to treat ADPKD outside of the FDA-approved risk evaluation and mitigation strategy (REMS) for ADPKD patients [see Contraindications (4)].

Patients with symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice should discontinue treatment with tolvaptan.

Limit duration of therapy with tolvaptan to 30 days. Avoid use in patients with underlying liver disease, including cirrhosis, because the ability to recover from liver injury may be impaired [see Adverse Reactions (6.1)].
Amiloride HCl is indicated as adjunctive treatment with thiazide diuretics or other kaliureticdiuretic agents in congestive heart failure or hypertension to:

  * help restore normal serum potassium levels in patients who develop hypokalemia on the kaliuretic diuretic. 
  * prevent development of hypokalemia in patients who would be exposed to particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. 



The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride HCl has little additive diuretic or antihypertensive effect when added to a thiazide diuretic.

Amiloride HCl should rarely be used alone. It has weak (compared with thiazides) diuretic and antihypertensive effects. Used as single agents, potassium sparing diuretics, including amiloride HCl, result in an increased risk of hyperkalemia (approximately 10% with amiloride). Amiloride HCl should be used alone only when persistent hypokalemia has been documented and only with careful titration of the dose and close monitoring of serum electrolytes.
PURPOSE: To assess the association of postoperative C-reactive protein (CRP), leucocytes and vital signs in the first three postoperative days (PODs) with major complications after oncological colorectal resections in a tertiary referral centre for colorectal cancer in The Netherlands.
METHODS: A retrospective cohort study, including 594 consecutive patients who underwent an oncological colorectal resection at Maastricht University Medical Centre between January 2016 and December 2020. Descriptive analyses of patient characteristics were performed. Logistic regression models were used to assess associations of leucocytes, CRP and Modified Early Warning Score (MEWS) at PODs 1-3 with major complications. Receiver operating characteristic curve analyses were used to establish cut-off values for CRP.
RESULTS: A total of 364 (61.3%) patients have recovered without any postoperative complications, 134 (22.6%) patients have encountered minor complications and 96 (16.2%) developed major complications. CRP levels reached their peak on POD 2, with a mean value of 155 mg/L. This peak was significantly higher in patients with more advanced stages of disease and patients undergoing open procedures, regardless of complications. A cut-off value of 170 mg/L was established for CRP on POD 2 and 152 mg/L on POD 3. Leucocytes and MEWS also demonstrated a peak on POD 2 for patients with major complications.
CONCLUSIONS: Statistically significant associations were found for CRP, Δ CRP, Δ leucocytes and MEWS with major complications on POD 2. Patients with CRP levels ≥ 170 mg/L on POD 2 should be carefully evaluated, as this may indicate an increased risk of developing major complications.
The present invention relates to and a kind ofly comprise the pharmaceutical composition of Decaspermum fruticosum J.K. Et G. Forse. extract as active component for prevention and therapy diseases associated with inflammation or asthma.The increase of the eosinophilic granulocyte in the bronchoalveolar lavage fluid of the animal model in asthma that Decaspermum fruticosum J.K. Et G. Forse. extract of the present invention can suppress ovalbumin to be induced, there is the activity suppressing immunoglobulin and chemotactic factor (eotaxin) secretions in bronchoalveolar lavage fluid and blood, and suppress NO and the TNF-α secretions in macrophage.Therefore, Decaspermum fruticosum J.K. Et G. Forse. extract of the present invention can be effectively used as the active component of the pharmaceutical composition of prevention and therapy diseases associated with inflammation or asthma, and prevention and improve the active component of health functional food of diseases associated with inflammation or asthma.
These patients are COVID-19 positive; ages \> 18 and \< 70 years old; require \> 2 liters of oxygen by nasal cannula to maintain SpO2 \> 90%; are admitted to the sixth floor at University Hospital, on one of two designated Hospitalist services (approximately 16 COVID-19 positive patients/service). Patients in the study cohort will also be monitored with a CipherOx CR T1 tablet in a continuous manner to determine if maintaining CRI vales between 0.9-0.7 will: 1) help guide IV fluid (e.g. crystalloid, colloids, blood products) and medication therapy (e.g. diuretics); 2) allows earlier identification of patients who are poorly compensating and will require ICU level care; 3) reduces AKI and/or need for CRRT; and 4) improves clinical outcomes.
In the control group, a conventional intervention will be used, and health education brochures on the COVID-19 vaccine will be distributed for the study participants to read on their own time. The contents of the brochure included basic knowledge concerning the SARS-CoV-2 coronavirus, COVID-19 vaccine, herd immunity, and precautions for vaccination.
Participants over 18 years of age admitted to the ICU in the selected hospitals during the study period, using intracranial pressure monitoring catheters and/or external ventricular drain. Baseline database obtained from the study "Device-related Central Nervous System Infections in Adult Intensive Care Units in Brazil (IMPACTO-SNC)", Carried out during the period from 2022 to 2023.
Sustained release pharmaceutical compositions for oral administration comprise a homogeneous mixture of one or more drugs with one or more digestible fatty materials, one or more swelling agents, and one or more digestion-resistant waxy materials in a proportion not exceeding 10% of the total weight of the composition.  Digestible fatty materials are glyceryl mono- or tri-stearate, or mono- or tri-oleate, stearic or oleic acid, diglycol stearate, or calcium or magnesium stearate.  Swelling agents are proteins such as gluten and casein, or cellulose ethers such as methyl cellulose, carboxymethyl cellulose, hydroxyethylcellulose, and their non-toxic metal salts (e.g. sodium). Waxy materials are cetyl alcohol, solid and liquid paraffinic hydrocarbons, or bees wax, carnauba wax, bay berry wax and palm wax. The compositions may be prepared either by melting and mixing the components or dissolving them in a suitable solvent, mixing, and evaporating the solvent.  The compositions may be employed in a liquid state as a coating composition, or granulated, optionally with fillers and lubricants, and then formed into tablets, or else the granules may be coated and coloured and filled into capsules, optionally as a mixture of granules having different release rates or containing different drugs.  Examples are given for the preparation of amphetamine-containing granules, which are tabletted and also encapsulated.
INTRODUCTION: The prolongation and consequences of the COVID-19 pandemic have led to an uncertain and devastating panorama in many populations, and the evidence shows a high prevalence of mental health problems in medical students. The objective was to evaluate the association between mood disorders and sleep quality (SQ) in Peruvian medical students during the COVID-19 pandemic.
METHODS: A cross-sectional study was conducted on 310 medical students from a private university in Peru. The SQ was measured using the Pittsburgh Sleep Quality Index (PSQI), while mood disorders were evaluated using the Depression Anxiety and Stress Scale-21 (DASS-21). All information was collected by online surveys and then analysed in the R programming language.
RESULTS: The SQ results measured by PSQI were poor in 83.9% of the medical students. In the Poison regression analysis, the results of the bivariate analysis in men show that all mood disorders found the prevalence of poor SQ. However, in the multivariate analysis only stress (PRa=1.30; 95% CI, 1.08-1.57; P<0.01) and anxiety (PRa=1.34; 95% CI, 1.09-1.56; P <0.01) increased the prevalence of poor SQ. Women had a similar pattern in bivariate analysis, whereas in multivariate analysis, only severe stress (PRa=1.15; 95% CI, 1.01-1.29; P <0.05) increased the prevalence of poor SQ.
CONCLUSIONS: This study allows us to observe the consequences that the COVID-19 pandemic is having on medical students in Peru. It also revealed a population group vulnerable to poor quality of sleep and bad mood, which in the future will impact on health. It is suggested to educate medical students about the importance of proper sleep hygiene and the consequences of poor sleep hygiene practices.
The present invention discloses a remote network management system for coupling a series of remote serial devices (111a, 111b), servers (113a, 113b), and computers (115a, 115b) to one or more user workstations (101) allowing for selective access of the remote devices. The remote serial devices, servers, and computers are all connected to a remote management unit (109) which interfaces the user workstations to the remote devices. The power supply of each remote device is also connected to the remote management unit through a controllable power supply. The video from the remote networking equipment is digitized and optimized by an LCD controller located within the remote management unit before it i compressed for transmission. An option menu containing a menu of all the remote devices allows a user to select and operate any of the remote devices. The option menu is also utilizes to selectively control the power to the remote serial devices (111a, 111b), servers (113a, 113b), and computers (115a, 115b).
The present invention relates to an application of arecoline hydrobromide as an antiarrhythmic drug. Arecoline hydrobromide (areoline hydrobronide, Are) is alkaloidal hydrobromate extracted from betel nut seeds of palm plants. The present invention uses the Are as an antiarrhythmic drug, especially an effective ingredient of the antiarrhythmic drug of a third class. A research result shows that the Are has the effect on resisting multiple experimental arrhythmia caused by aconitine, ouabain, chloroform-epinephrine, calcium chloride, ischemic reperfusion, etc., and has a main mechanism that calcium, sodium and potassium ion currents on myocardial cell membranes are direct blocked, and thereby, action potential duration is extends in the way of concentration dependence and frequency dependence. Thus, the Are has the use of the antiarrhythmic drug of a third class of the characteristics of both of partial antiarrhythmic drugs of a first class and a fourth class. Because the application has the electric physiological characteristics influencing myocardial cells in the way of multiple channels and multiple links, fewer adverse reactions occur, and especially the possibility of causing new arrhythmia action is lower. Thus, the Are has very wide application prospects as the antiarrhythmic drug.